These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

523 related articles for article (PubMed ID: 33411241)

  • 1. Cholesterol Metabolism in Neurodegenerative Diseases: Molecular Mechanisms and Therapeutic Targets.
    Dai L; Zou L; Meng L; Qiang G; Yan M; Zhang Z
    Mol Neurobiol; 2021 May; 58(5):2183-2201. PubMed ID: 33411241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential Use of the Cholesterol Transfer Inhibitor U18666A as a Potent Research Tool for the Study of Cholesterol Mechanisms in Neurodegenerative Disorders.
    Yasamineh S; Mehrabani FJ; Derafsh E; Danihiel Cosimi R; Forood AMK; Soltani S; Hadi M; Gholizadeh O
    Mol Neurobiol; 2024 Jun; 61(6):3503-3527. PubMed ID: 37995080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dysregulation of cholesterol balance in the brain: contribution to neurodegenerative diseases.
    Vance JE
    Dis Model Mech; 2012 Nov; 5(6):746-55. PubMed ID: 23065638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statins: multiple neuroprotective mechanisms in neurodegenerative diseases.
    Wang Q; Yan J; Chen X; Li J; Yang Y; Weng J; Deng C; Yenari MA
    Exp Neurol; 2011 Jul; 230(1):27-34. PubMed ID: 20406638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Linking lipids to Alzheimer's disease: cholesterol and beyond.
    Di Paolo G; Kim TW
    Nat Rev Neurosci; 2011 May; 12(5):284-96. PubMed ID: 21448224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The beneficial effects of HMG-CoA reductase inhibitors in the processes of neurodegeneration.
    Saeedi Saravi SS; Saeedi Saravi SS; Arefidoust A; Dehpour AR
    Metab Brain Dis; 2017 Aug; 32(4):949-965. PubMed ID: 28578514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging role of HDL in brain cholesterol metabolism and neurodegenerative disorders.
    Turri M; Marchi C; Adorni MP; Calabresi L; Zimetti F
    Biochim Biophys Acta Mol Cell Biol Lipids; 2022 May; 1867(5):159123. PubMed ID: 35151900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LXR Regulation of Brain Cholesterol: From Development to Disease.
    Courtney R; Landreth GE
    Trends Endocrinol Metab; 2016 Jun; 27(6):404-414. PubMed ID: 27113081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain cholesterol homeostasis and its association with neurodegenerative diseases.
    Gao Y; Ye S; Tang Y; Tong W; Sun S
    Neurochem Int; 2023 Dec; 171():105635. PubMed ID: 37949118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholesterol metabolism and homeostasis in the brain.
    Zhang J; Liu Q
    Protein Cell; 2015 Apr; 6(4):254-64. PubMed ID: 25682154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of 3-Hydroxyl 3-Methylglutaryl CoA Reductase in Alzheimer's Disease.
    Zhou X; Wu X; Wang R; Han L; Li H; Zhao W
    Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mevalonate Cascade and Neurodevelopmental and Neurodegenerative Diseases: Future Targets for Therapeutic Application.
    Jiao X; Ashtari N; Rahimi-Balaei M; Chen QM; Badbezanchi I; Shojaei S; Marzban A; Mirzaei N; Chung S; Guan T; Li J; Vriend J; Mehr SE; Kong J; Marzban H
    Curr Mol Pharmacol; 2017; 10(2):115-140. PubMed ID: 26758948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of cholesterol and statins on Parkinson's neuropathology: a narrative review.
    Al-Kuraishy HM; Fahad EH; Al-Windy S; El-Sherbeni SA; Negm WA; Batiha GE
    Inflammopharmacology; 2024 Apr; 32(2):917-925. PubMed ID: 38499742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholesterol Metabolism in Neurodegenerative Diseases.
    He K; Zhao Z; Zhang J; Li D; Wang S; Liu Q
    Antioxid Redox Signal; 2024 Jul; ():. PubMed ID: 38842175
    [No Abstract]   [Full Text] [Related]  

  • 15. Lipid integration in neurodegeneration: an overview of Alzheimer's disease.
    Yadav RS; Tiwari NK
    Mol Neurobiol; 2014 Aug; 50(1):168-76. PubMed ID: 24590317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pros and cons for statins use and risk of Parkinson's disease: An updated perspective.
    Al-Kuraishy HM; Al-Gareeb AI; Alexiou A; Papadakis M; Alsayegh AA; Almohmadi NH; Saad HM; Batiha GE
    Pharmacol Res Perspect; 2023 Apr; 11(2):e01063. PubMed ID: 36811160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholesterol Metabolism in the Brain and Its Association with Parkinson's Disease.
    Jin U; Park SJ; Park SM
    Exp Neurobiol; 2019 Oct; 28(5):554-567. PubMed ID: 31698548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prescription of lipophilic statins to Alzheimer's disease patients: some controversies to consider.
    Biondi E
    Neurol Sci; 2011 Apr; 32(2):195-201. PubMed ID: 20957505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholesterol involvement in the pathogenesis of neurodegenerative diseases.
    Liu JP; Tang Y; Zhou S; Toh BH; McLean C; Li H
    Mol Cell Neurosci; 2010 Jan; 43(1):33-42. PubMed ID: 19660552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brain Cholesterol Metabolism and Its Defects: Linkage to Neurodegenerative Diseases and Synaptic Dysfunction.
    Petrov AM; Kasimov MR; Zefirov AL
    Acta Naturae; 2016; 8(1):58-73. PubMed ID: 27099785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.